IO Biotech, Inc. · OTC:IOBTQ
IO Biotech — Investor Presentation (May 2025)
33 slides from IO Biotech's investor presentation, May 2025
Slide 1: Break Boundaries. Ignite Change. Corporate Presentation
Break Boundaries. Ignite Change. Nasdaq: IOBT Corporate Presentation May 2025 © 2025 IO Biotech, Inc.
Slide 2: Disclaimer | Forward Looking Statements
DISCLAIMER | Forward Looking Statements Certain information contained in this presentation includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our business pl
Slide 3: Break Boundaries. Ignite Change.
BREAK BOUNDARIES. IGNITE CHANGE. Cylembio is the US Brand Name for IO102-IO103 3
Slide 4: The Patient Journey
Expected to be available THE PATIENT JOURNEY across all sites of care Off-the-shelf product candidate Rapid subcutaneous Disease Presentation 1 Primary Care Physician or administration Dermatologist Cylembio will, if Unresectable or Metastatic Melanoma approved, be Diagnosis & Referral 4 ~15,000 pat
Slide 5: Highlights
HIGHLIGHTS | BREAK BOUNDARIES. IGNITE CHANGE. STRONG PLATFORM AND CLINICAL PROOF-OF- PRODUCT POTENTIALLY ON PIPELINE CONCEPT ESTABLISHED THE MARKET IN 2026 1 T-win® platform delivering investigational, immune- modulatory, off-the-shelf therapeutic cancer vaccines Ph1/2 Clinical proof-of- concept est
Slide 6: Our Lead Indication: First-line advanced melanoma
OUR LEAD INDICATION: First-line advanced melanoma 1 OUR PIPELINE: NSCLC, SCCHN, Neoadjuvant/adjuvant 2 OUR PLATFORM 3 GROWTH STRATEGY and OUTLOOK 4 IO BIOTECH TEAM and COMPANY HISTORY (backup) 5 6
Slide 7: Unmet Need in Advanced Melanoma
UNMET NEED IN ADVANCED MELANOMA | IO Biotech aims to address the unmet need for 1L advanced melanoma patients Melanoma is a growing and The global melanoma market is Patients and physicians seek more common cancer expected to reach >$13B by 20304 effective treatment options5-8 5th most diagnosed can
Slide 8: Melanoma | Phase 1/2 outcomes published in Nature Medicine
Phase 1/2 MM1636 Melanoma MELANOMA | Successful outcomes from Phase 1/2 were published in Nature Medicine and drove continued clinical development for 1L melanoma Compelling Data Published in Nature Medicine Results showing an attractive safety profile December 09, 2021 January 2023 Data Cut* as Pub
Slide 9: Melanoma | Phase 3 fully enrolled, readout expected 3Q25
Phase 3 IOB-013/KN-D18 Melanoma MELANOMA | Treatment for 1L melanoma is currently in Phase 3, fully enrolled with primary endpoint readout expected in 3Q25 Clinical trial design Eligibility criteria Stratification Randomization Endpoints Planned 380 PRIMARY ENDPOINT • Advanced melanoma IO102-IO103 a
Slide 10: Melanoma | Physician feedback on Cylembio
MELANOMA | Physician feedback highlights the potential of IO Biotech’s vaccine candidate Cylembio® (imsapepimut and etimupepimut, adjuvanted) (if) the ORR is Excited to help Encouraging that superior to ipi + nivo, more patients and there are no trade- this product will see how benefit offs between
Slide 11: Launch Goals | Establish Cylembio as new standard of care
LAUNCH GOALS | Opportunity to establish Cylembio as a new standard of care for patients with advanced melanoma PILLARS FOR A SUCCESSFUL LAUNCH LAUNCH GOALS TO ENSURE RAPID ADOPTION AT LAUNCH Potentially practice Establish belief in potentially transformative clinical changing Cylembio 1 benefit of C
Slide 12: Our Pipeline: NSCLC, SCCHN, Neoadjuvant/adjuvant
OUR LEAD INDICATION: First-line advanced melanoma 1 OUR PIPELINE: NSCLC, SCCHN, Neoadjuvant/adjuvant 2 OUR PLATFORM 3 GROWTH STRATEGY and MILESTONES 4 IO BIOTECH TEAM and COMPANY HISTORY (backup) 5 12
Slide 13: Pipeline | T-win platform with product candidates in multiple cancer indications
PIPELINE | The T-win® platform with 3 product candidates in multiple cancer indications Product Line of therapy/ Pre-clinical Phase 1 Phase 2 Phase 3 Takeaways candidates indication IOB-013: First Line Phase 3 pivotal trial primary Advanced Melanoma* endpoint, PFS, expected to read out in 3Q 2025 IO
Slide 14: Unmet Need in Advanced NSCLC
UNMET NEED IN ADVANCED NSCLC | IO Biotech aims to improve patient outcomes in hard-to-treat cancers NSCLC corresponds to 85% of Global NSCLC market is expected An unmet need remains5-7 due to lung cancer diagnosis1-3 to reach ∼$60B 20303 complex nature of the disease 2nd most diagnosed cancer worldw
Slide 15: Unmet Need in Advanced SCCHN
UNMET NEED IN ADVANCED SCCHN | IO Biotech aims to improve patient outcomes in hard-to-treat cancers SCCHN is a life-threatening Global SCCHN market is expected An unmet need remains 4 for disease with poor prognosis 1-2 to reach ∼$5B by 20303 patients with advanced SCCHN 6th most diagnosed cancer in
Slide 16: SCCHN & NSCLC | Encouraging data from ongoing Phase 2 trial
Phase 2 IOB-022/KN-D38 Solid Tumor Basket SCCHN & NSCLC | Encouraging data in head & neck and lung cancer from ongoing Phase 2 trial Clinical trial design Eligibility criteria Cohorts1 Treatment Endpoints PRIMARY ENDPOINT • ORR • Previously untreated A: NSCLC metastatic solid tumors PD- L1 TPS ≥ 50%
Slide 17: NSCLC | Promising data presented at SITC 2024
Phase 2 IOB-022/KN-D38 Solid Tumor Basket NSCLC | Promising data presented at SITC 2024 Encouraging data for the NSCLC cohort PFS and Confirmed Objective Response Best overall response, n (%) RECIST 1.1 N = 31* 48 [30-67] confirmed/ ORR (95% CI)* 55 [36-73] unconfirmed Complete Response (CR) 1 (3.2)
Slide 18: SCCHN | Primary endpoint met
Phase 2 IOB-022/KN-D38 Solid Tumor Basket SCCHN | Primary endpoint met Encouraging preliminary data for the SCCHN cohort Treatment duration, time to response and best overall response per RECIST 1.1 Best overall response, n (%) RECIST 1.1 N = 18* ORR (95% CI)* 44.4 [21.5; 69.2] Partial Response (PR)
Slide 19: Totality of Clinical Data Is Compelling
TOTALITY OF CLINICAL DATA IS COMPELLING | IOBT is building on the body of evidence of Cylembio® across multiple tumor types and settings Starting with proof of concept in advanced FIRST-LINE ADVANCED MELANOMA melanoma… Results from Phase 1/2 (MM1636): 80% ORR*, 50% CR, 25.5 months PFS Status: Curren
Slide 20: Clinical Trials | Expanding into neoadjuvant/adjuvant treatment
Phase 2 IOB-032/KN-D40 Neoadjuvant/adjuvant Basket Trial CLINICAL TRIALS | Expanding beyond advanced diseases into the neoadjuvant/adjuvant treatment; fully enrolled Phase 2 basket study Clinical trial design Eligibility criteria Cohorts Neoadjuvant phase Surgery and recovery Adjuvant phase 15 cycle
Slide 21: Addressable Patients
ADDRESSABLE PATIENTS | Cylembio with potential to redefine treatment of hard-to-treat solid tumors and expanding beyond 1L advanced melanoma 3 Expand to earlier lines Total addressable patients (US) Peri-operative Peri-operative SCCHN melanoma >100,000 patients1 2 Advance to other hard-to-treat tumo
Slide 22: Pre-clinical Pipeline | Arginase 1 program; IND filing expected 2025
PRE-CLINICAL PIPELINE | Expanding the clinical portfolio with Arginase 1 program; IND filing expected in 2025 • Arginase 1 vaccine Pre-clinical pipeline opportunities candidate controls tumor Two preclinical growth in animal models via programs in solid IO112 direct targeting of Arg1+ tumors showing
Slide 23: Our Platform
OUR LEAD INDICATION: First-line advanced melanoma 1 OUR PIPELINE: NSCLC, SCCHN, Neoadjuvant/adjuvant 2 OUR PLATFORM 3 GROWTH STRATEGY and OUTLOOK 4 IO BIOTECH TEAM and COMPANY HISTORY (backup) 5 23
Slide 24: Platform | T-Win therapeutic cancer vaccines activate the immune system
PLATFORM | T-Win® therapeutic cancer vaccines activate the immune system, targeting both tumor cells and immune-suppressive cells in the TME The T-win® platform provides a new therapeutic strategy that may improve patient outcomes with a novel mechanism of action that addresses multiple TME suppress
Slide 25: Off-the-Shelf Treatment
OFF-THE-SHELF TREATMENT | IOBT’s immune-modulatory therapeutic cancer vaccine candidates designed to ensure all eligible patients can receive treatment without delay* A 4 steps process from Cylembio® (imsapepimut and etimupepimut, adjuvanted) production to the patient vaccination… GMP Manufacturing
Slide 26: Growth Strategy and Outlook
OUR LEAD INDICATION: First-line advanced melanoma 1 OUR PIPELINE: NSCLC, SCCHN, Neoadjuvant/adjuvant 2 OUR PLATFORM 3 GROWTH STRATEGY and OUTLOOK 4 IO BIOTECH TEAM and COMPANY HISTORY (backup) 5 26
Slide 27: Milestones | Important clinical milestones expected through 2025
MILESTONES | Important clinical milestones expected through 2025 Cash into 2Q2026 including first three tranches of EIB loan facility and 1Q cash balance of $37M* H1 2025 H2 2025 2026 Cylembio | 1L Readout of primary endpoint expected 3Q25 Potential US approval Advanced Melanoma Potential BLA
Slide 28: Driving the Next Frontier of Immunotherapy
DRIVING THE NEXT FRONTIER OF IMMUNOTHERAPY | Cylembio®, a potential first-in-class, immune-modulatory, off-the-shelf therapeutic cancer vaccine candidate POISED FOR SUCCESS WITH POTENTIAL CYLEMBIO® LAUNCH BUILDING UPON SEVERAL SUCCESSFUL MILESTONES Compelling Phase 1/2 data in metastatic Significant
Slide 29: Highlights
HIGHLIGHTS | BREAK BOUNDARIES. IGNITE CHANGE. STRONG PLATFORM AND CLINICAL PROOF-OF- PRODUCT POTENTIALLY ON PIPELINE CONCEPT ESTABLISHED THE MARKET IN 2026 1 T-win® platform delivering investigational, immune- modulatory, off-the-shelf therapeutic cancer vaccines Ph1/2 Clinical proof-of- concept est
Slide 30: IO Biotech Team and Company History (backup)
OUR LEAD INDICATION: First-line advanced melanoma 1 OUR PIPELINE: NSCLC, SCCHN, Neoadjuvant/adjuvant 2 OUR PLATFORM 3 GROWTH STRATEGY and OUTLOOK 4 IO BIOTECH TEAM and COMPANY HISTORY (backup) 5 30
Slide 31: The Team | Management team
THE TEAM | We have a strong management team with large biopharma and biotech experience Mai-Britt Zocca, PhD Amy Sullivan, MBA Devin Smith Qasim Ahmad, MD President and Chief Chief Financial Officer General Counsel Chief Medical Officer Executive Officer Faiçal Miyara, PhD Eric Faulkner, MBA Dan Man
Slide 32: The Team | Board of Directors and Scientific Advisory Board
THE TEAM | Our management team is supported by the Board of Directors and the Scientific Advisory Board Board of Directors Scientific Advisory Board Peter Hirth, Ph.D. Kathleen Sereda Christian Elling, Ph.D. Helen Collins, M.D. Kapil Dhingra, M.D. Mads Hald Andersen, Chairman Glaub, M.B.A. Member –
Slide 33: IOBT History
IOBT HISTORY | Since its foundation in 2014, IO Biotech has built a strong platform and has the potential for US market launch in 2026 Company creation and Building a strong platform and initiating clinical trials Significant upcoming milestones securing financing $150 million Series B IOB-022 – ph2